All In Biotech

Drug Trial Radar · NCT01730404

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

A Randomised, Double-blind, Double-dummy, Placebo and Active-controlled, Three-way Crossover Study to Evaluate the Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI (1200 µg Daily) in Subjects With COPD

Last checked: Nov 19, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Oct 2012

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Nov 21, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF 6001 (a PDE4 inhibitor) after 28-days of daily inhaled dosing.

Conditions

  • COPD

Interventions

  • CHF6001 DPIDrug

  • RoflumilastDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events, adverse drug reactions, serious adverse.Time frame: After 28 days of treatment
  2. Vital signsTime frame: After 28 days of treatment
  3. 12-lead ECG parametersTime frame: After 28 days of treatment

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Celerion

    Belfast, Ireland

  • Parexel, early phases

    Harrow, United Kingdom

  • Medicines Evaluation Unit Ltd

    Manchester, United Kingdom

  • Freeman Hospital

    Newcastle, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.